Peptide Therapeutics Market

Peptide Therapeutics Market (Application: Metabolic, Oncology, Gastrointestinal, Cardiovascular, Neurological, and Others; and Route of Administration: Parenteral, Oral, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Peptide Therapeutics Market Outlook 2031

  • The global industry was valued at US$ 37.8 Bn in 2022
  • It is projected to grow at a CAGR of 9.6% from 2023 to 2031 and reach more than US$ 85.9 Bn by the end of 2031

Analysts’ Viewpoint

Development of innovative delivery technologies and advancements in medical expertise are expected to fuel the peptide therapeutics market size. PEGylation is a popular trend in the peptide drug chemical structure, which improves pharmacologic properties by increasing half-life, reducing antigenicity and immunogenicity, and improving solubility.

Overcoming challenges of oral peptide delivery, such as formulating peptides with excipients, using absorption enhancers, targeting specific cells or tissues, and developing peptide-based prodrugs that are converted to active peptides after absorption are likely to drive peptide therapeutics market growth. The rise in interest in peptide-based therapeutic vaccines is also likely to further drive market progress. The market is predicted to remain a lucrative sector in the coming years and continue to experience healthy growth.

Peptide Therapeutics Market

Market Introduction

Peptide therapeutics are increasingly used in the treatment of cancer, metabolic disorders, and in hormonal therapy. The growth in peptide applications for diabetes, obesity, osteoarthritis, and osteoporosis is further projected to boost the industry. Advancement of sophisticated drug delivery methods, as well as surge in funding in this sector, are predicted to have a disruptive influence on the field of peptide-based medicine.

The development of oral peptide therapeutics, which offer several advantages over injectable peptide drugs, such as improved patient convenience and compliance, a lower risk of infection and other complications associated with injections, and the potential to reach a broader range of patients, is expected to offer lucrative opportunities for market expansion. Additionally, the development of cyclized peptides, which are more often generated due to their enhanced conformational stability, is projected to propel market statistics.

The development of oral peptide therapies, cyclized peptides, and other breakthroughs in the industry are likely to further act as market catalysts.

Rise in Prevalence of Chronic Diseases Fueling Peptide Therapeutics Market Development

Rise in prevalence of chronic diseases is driving demand for new treatments and augmenting the peptide therapeutics market value. According to the Centers for Disease Control and Prevention (CDC), six in ten adults in the United States have at least one chronic disease, and four in ten have two or more. Cancer is the second leading cause of death worldwide, accounting for 9.9 million deaths in 2020, and the prevalence of diabetes in the US has increased from 8.0% in 2010 to 10.2% in 2020.

Peptide therapeutics offer numerous advantages over traditional small molecule and biologic therapies. A 2021 study found that semaglutide, a peptide therapeutic, was effective in reducing blood sugar levels and improving cardiovascular outcomes in type 2 diabetes patients. Peptide application in cancer treatment also provides promising opportunities for future growth in the peptide therapeutics market.

Significant R&D in Innovative Peptide Therapeutics

The peptide therapeutics market segmentation in terms of product type includes innovative, and generic. The innovative segment accounted for largest global peptide therapeutics industry share in 2022. Huge investments made by market players in research and development activities of innovative products is driving market dynamics. Large number of revenue- generating peptide drugs come under this category.

Rise in Prevalence of Metabolic Illnesses

Based on application, the metabolic segment dominated the global market demand in 2022. Sedentary lifestyles, rapid rise in geriatric population, and increase in frequency of metabolic illnesses is influencing the growth to the segment. Because peptide therapies may be engineered to target specific receptors or enzymes involved in metabolic processes, they offer several benefits such as high specificity, minimal toxicity, and good tolerance.

The metabolic category is viewed as a highly profitable application by major pharmaceutical firms. The growing use of peptides to treat metabolic illnesses such as diabetes, obesity, osteoarthritis, and osteoporosis is likely to drive segment growth and fuel peptide therapeutics market opportunities.

High Demand for Native Peptides

The peptide therapeutics market analysis based on types of peptides includes native peptides, analog peptides, and heterologous peptides. The native peptides segment held significant share in 2022. Native peptides have become increasingly attractive for therapeutic development due to their improved safety, efficacy, and tolerability compared to synthetic peptides or other drug classes. Their inherent safety advantage is the major factor contributing to their projected dominance in the market.

Cost-effectiveness of In-house Manufacturing

Based on manufacturing type, the market is categorized into in-house, and CMO. The in-house segment dominated the global market in 2022. Cost-effectiveness, flexibility, confidentiality, and iterative synthesis approaches are key factors driving the segment. Researchers can customize peptide length, sequence, modifications, and purity to suit their research objectives.

Regional Outlook

As per the latest peptide therapeutics market forecast, North America dominated the global industry in 2022, ascribed to the presence of key drug manufacturers such as Novo Nordisk A/S., Eli Lilly and Company, and AstraZeneca, who are actively investing in research and development of novel therapies.

Asia Pacific holds a significant share of the global market. Rise in diabetes and cancer prevalence in countries such as China, India, and Japan, due to aging populations, and lifestyle & environmental changes are likely to drive market demand in the region.

Analysis of Key Players

Leading players in the global peptide therapeutics market have adopted strategies such as product portfolio expansion, and mergers & acquisition in order to increase market share.

Amgen, Inc., Sachem Holding AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Novartis AG, Pfizer, Inc., Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. are the prominent players in the market.

Key players have been profiled in the global peptide therapeutics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments

  • On September 14, 2023, the FDA issued draft guidance on clinical pharmacology and labeling for peptide drug products, advising against radiolabeled mass balance studies and requiring immunogenicity risk assessment for all products. The FDA acknowledges potential hepatic impairment impacting certain peptide drug products' pharmacokinetics.
  • On June 26, 2023, Asep Medical received a US$ 200,000 grant from the NanoMedicines Innovation Network to develop a nanoparticle-formulated peptide solution for treating chronic sinus infections caused by biofilms. The grant, funded by Canada's Networks of Centres of Excellence, will aid pre-clinical studies and clinical trials.
  • On March 18, 2023, Fujitsu launched its "Biodrug Design Accelerator" platform, aiming to accelerate peptide drug discovery research. As part of its "Healthy Living" vision, it supports scientists through the "design, make, test, analyze" cycle, enabling informed design of peptide drug candidates and efficient communication. The platform is compatible with HELM and will expand to support nucleic acid and antibody drugs.

Global Peptide Therapeutics Market Snapshot

Attribute Detail
Market Value in 2022 US$ 37.8 Bn
Forecast (Value) in 2031 US$ 85.9 Bn
Growth Rate (CAGR) 9.6%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It provides segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Product Type
    • Innovative
    • Generic
  • Application
    • Metabolic
    • Oncology
    • Gastrointestinal
    • Cardiovascular
    • Neurological
    • Others
  • Route of Administration
    • Parenteral
    • Oral
    • Others
  • Types of Peptide
    • Native Peptides
    • Analog Peptides
    • Heterologous Peptides
  • Technology
    • Liquid Phase
    • Solid phase
    • Hybrid
  • Manufacturing Type
    • In-house
    • CMO
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries
Companies Profiled
  • Amgen, Inc.
  • Sachem Holding AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global peptide therapeutics market in 2022?

It was valued at US$ 37.8 Bn in 2022

How big will the peptide therapeutics business be in 2031?

It is projected to reach more than US$ 85.9 Bn by 2031

What will be the CAGR of the peptide therapeutics industry during the forecast period (2023–2031)?

The CAGR is projected to be 9.6% from 2023 to 2031

Which are the key trends driving demand for peptide therapeutics?

Increase in prevalence of metabolic disorders and precise control over dosage

Which region is likely to account for major share of the peptide therapeutics sector during the forecast period?

North America is projected to account for major share during the forecast period

Who are the prominent peptide therapeutics vendors?

Amgen, Inc., Sachem Holding AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Novartis AG, Pfizer, Inc., Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Peptide Therapeutics Market

    4. Market Overview

        4.1. Introduction

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Peptide Therapeutics Market Analysis and Forecasts, 2023-2031

    5. Key Insights

        5.1. FDA-approved Peptide Therapeutics in 2022

        5.2. Peptide Drugs Approved Since 2000, with their Targets and Indications

        5.3. White Space Analysis

        5.4. Porter's Analysis

        5.5. Pipeline Analysis

        5.6. Peptide Drugs Chemical Structure Trend Analysis

        5.7. Separation Media Used for Peptide Drugs

        5.8. COVID-19 Impact Analysis

    6. Global Peptide Therapeutics Market Analysis and Forecasts, By Product Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast By Product Type, 2023-2031

            6.3.1. Innovative

            6.3.2. Generic

        6.4. Market Attractiveness By Product Type

    7. Global Peptide Therapeutics Market Analysis and Forecasts, By Application

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast By Application, 2023-2031

            7.3.1. Metabolic

            7.3.2. Oncology

            7.3.3. Gastrointestinal

            7.3.4. Cardiovascular

            7.3.5. Neurological

            7.3.6. Others

        7.4. Market Attractiveness By Application

    8. Global Peptide Therapeutics Market Analysis and Forecasts, By Route of Administration

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast By Route of Administration, 2023-2031

            8.3.1. Parenteral

            8.3.2. Oral

            8.3.3. Others

        8.4. Market Attractiveness By Route of Administration

    9. Global Peptide Therapeutics Market Analysis and Forecasts, By Types of Peptide

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast By Types of Peptide, 2023-2031

            9.3.1. Native Peptides

            9.3.2. Analog Peptides

            9.3.3. Heterologous Peptides

        9.4. Market Attractiveness By Types of Peptide

    10. Global Peptide Therapeutics Market Analysis and Forecasts, By Technology

        10.1. Introduction & Definition

        10.2. Key Findings / Developments

        10.3. Market Value Forecast By Technology, 2023-2031

            10.3.1. Liquid Phase

            10.3.2. Solid Phase

            10.3.3. Hybrid

        10.4. Market Attractiveness By Technology

    11. Global Peptide Therapeutics Market Analysis and Forecasts, By Manufacturing Type

        11.1. Introduction & Definition

        11.2. Key Findings / Developments

        11.3. Market Value Forecast By Manufacturing Type, 2023-2031

            11.3.1. In-house

            11.3.2. CMO

        11.4. Market Attractiveness By Manufacturing Type

    12. Global Peptide Therapeutics Market Analysis and Forecasts, By Region

        12.1. Key Findings

        12.2. Market Value Forecast By Region

            12.2.1. North America

            12.2.2. Europe

            12.2.3. Asia Pacific

            12.2.4. Latin America

            12.2.5. Middle East & Africa

        12.3. Market Attractiveness By Country/Region

    13. North America Peptide Therapeutics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast By Product Type, 2023-2031

            13.2.1. Innovative

            13.2.2. Generic

        13.3. Market Value Forecast By Application, 2023-2031

            13.3.1. Metabolic

            13.3.2. Oncology

            13.3.3. Gastrointestinal

            13.3.4. Cardiovascular

            13.3.5. Neurological

            13.3.6. Others

        13.4. Market Value Forecast By Route of Administration, 2023-2031

            13.4.1. Parenteral

            13.4.2. Oral

            13.4.3. Others

        13.5. Market Value Forecast By Types of Peptide, 2023-2031

            13.5.1. Native Peptides

            13.5.2. Analog Peptides

            13.5.3. Heterologous Peptides

        13.6. Market Value Forecast By Technology, 2023-2031

            13.6.1. Liquid Phase

            13.6.2. Solid Phase

            13.6.3. Hybrid

        13.7. Market Value Forecast By Manufacturing Type, 2023-2031

            13.7.1. In-house

            13.7.2. CMO

        13.8. Market Value Forecast By Country, 2023-2031

            13.8.1. U.S.

            13.8.2. Canada

        13.9. Market Attractiveness Analysis

            13.9.1. By Product Type

            13.9.2. By Application

            13.9.3. By Route of Administration

            13.9.4. By Types of Peptide

            13.9.5. By Technology

            13.9.6. By Manufacturing Type

            13.9.7. By Country

    14. Europe Peptide Therapeutics Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast By Product Type, 2023-2031

            14.2.1. Innovative

            14.2.2. Generic

        14.3. Market Value Forecast By Application, 2023-2031

            14.3.1. Metabolic

            14.3.2. Oncology

            14.3.3. Gastrointestinal

            14.3.4. Cardiovascular

            14.3.5. Neurological

            14.3.6. Others

        14.4. Market Value Forecast By Route of Administration, 2023-2031

            14.4.1. Parenteral

            14.4.2. Oral

            14.4.3. Others

        14.5. Market Value Forecast By Types of Peptide, 2023-2031

            14.5.1. Native Peptides

            14.5.2. Analog Peptides

            14.5.3. Heterologous Peptides

        14.6. Market Value Forecast By Technology, 2023-2031

            14.6.1. Liquid Phase

            14.6.2. Solid Phase

            14.6.3. Hybrid

        14.7. Market Value Forecast By Manufacturing Type, 2023-2031

            14.7.1. In-house

            14.7.2. CMO

        14.8. Market Value Forecast By Country, 2023-2031

            14.8.1. Germany

            14.8.2. U.K.

            14.8.3. France

            14.8.4. Spain

            14.8.5. Italy

            14.8.6. Rest of Europe

        14.9. Market Attractiveness Analysis

            14.9.1. By Product Type

            14.9.2. By Application

            14.9.3. By Route of Administration

            14.9.4. By Types of Peptide

            14.9.5. By Technology

            14.9.6. By Manufacturing Type

            14.9.7. By Country

    15. Asia Pacific Peptide Therapeutics Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast By Product Type, 2023-2031

            15.2.1. Innovative

            15.2.2. Generic

        15.3. Market Value Forecast By Application, 2023-2031

            15.3.1. Metabolic

            15.3.2. Oncology

            15.3.3. Gastrointestinal

            15.3.4. Cardiovascular

            15.3.5. Neurological

            15.3.6. Others

        15.4. Market Value Forecast By Route of Administration, 2023-2031

            15.4.1. Parenteral

            15.4.2. Oral

            15.4.3. Others

        15.5. Market Value Forecast By Types of Peptide, 2023-2031

            15.5.1. Native Peptides

            15.5.2. Analog Peptides

            15.5.3. Heterologous Peptides

        15.6. Market Value Forecast By Technology, 2023-2031

            15.6.1. Liquid Phase

            15.6.2. Solid Phase

            15.6.3. Hybrid

        15.7. Market Value Forecast By Manufacturing Type, 2023-2031

            15.7.1. In-house

            15.7.2. CMO

        15.8. Market Value Forecast By Country, 2023-2031

            15.8.1. China

            15.8.2. Japan

            15.8.3. India

            15.8.4. Australia & New Zealand

            15.8.5. Rest of Asia Pacific

        15.9. Market Attractiveness Analysis

            15.9.1. By Product Type

            15.9.2. By Application

            15.9.3. By Route of Administration

            15.9.4. By Types of Peptide

            15.9.5. By Technology

            15.9.6. By Manufacturing Type

            15.9.7. By Country

    16. Latin America Peptide Therapeutics Market Analysis and Forecast

        16.1. Introduction

            16.1.1. Key Findings

        16.2. Market Value Forecast By Product Type, 2023-2031

            16.2.1. Innovative

            16.2.2. Generic

        16.3. Market Value Forecast By Application, 2023-2031

            16.3.1. Metabolic

            16.3.2. Oncology

            16.3.3. Gastrointestinal

            16.3.4. Cardiovascular

            16.3.5. Neurological

            16.3.6. Others

        16.4. Market Value Forecast By Route of Administration, 2023-2031

            16.4.1. Parenteral

            16.4.2. Oral

            16.4.3. Others

        16.5. Market Value Forecast By Types of Peptide, 2023-2031

            16.5.1. Native Peptides

            16.5.2. Analog Peptides

            16.5.3. Heterologous Peptides

        16.6. Market Value Forecast By Technology, 2023-2031

            16.6.1. Liquid Phase

            16.6.2. Solid Phase

            16.6.3. Hybrid

        16.7. Market Value Forecast By Manufacturing Type, 2023-2031

            16.7.1. In-house

            16.7.2. CMO

        16.8. Market Value Forecast By Country, 2023-2031

            16.8.1. Brazil

            16.8.2. Mexico

            16.8.3. Rest of Latin America

        16.9. Market Attractiveness Analysis

            16.9.1. By Product Type

            16.9.2. By Application

            16.9.3. By Route of Administration

            16.9.4. By Types of Peptide

            16.9.5. By Technology

            16.9.6. By Manufacturing Type

            16.9.7. By Country

    17. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast

        17.1. Introduction

            17.1.1. Key Findings

        17.2. Market Value Forecast By Product Type, 2023-2031

            17.2.1. Innovative

            17.2.2. Generic

        17.3. Market Value Forecast By Application, 2023-2031

            17.3.1. Metabolic

            17.3.2. Oncology

            17.3.3. Gastrointestinal

            17.3.4. Cardiovascular

            17.3.5. Neurological

            17.3.6. Others

        17.4. Market Value Forecast By Route of Administration, 2023-2031

            17.4.1. Parenteral

            17.4.2. Oral

            17.4.3. Others

        17.5. Market Value Forecast By Types of Peptide, 2023-2031

            17.5.1. Native Peptides

            17.5.2. Analog Peptides

            17.5.3. Heterologous Peptides

        17.6. Market Value Forecast By Technology, 2023-2031

            17.6.1. Liquid Phase

            17.6.2. Solid Phase

            17.6.3. Hybrid

        17.7. Market Value Forecast By Manufacturing Type, 2023-2031

            17.7.1. In-house

            17.7.2. CMO

        17.8. Market Value Forecast By Country, 2023-2031

            17.8.1. GCC Countries

            17.8.2. South Africa

            17.8.3. Rest of Middle East & Africa

        17.9. Market Attractiveness Analysis

            17.9.1. By Product Type

            17.9.2. By Application

            17.9.3. By Route of Administration

            17.9.4. By Types of Peptide

            17.9.5. By Technology

            17.9.6. By Manufacturing Type

            17.9.7. By Country

    18. Competition Landscape

        18.1. Market Player - Competition Matrix (By Tier and Size of companies)

        18.2. Market Share Analysis By Company (2022)

        18.3. Company Profiles

            18.3.1. Amgen, Inc.

                18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.1.2. Product Portfolio

                18.3.1.3. Financial Overview

                18.3.1.4. SWOT Analysis

                18.3.1.5. Strategic Overview

            18.3.2. Sachem Holding AG

                18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.2.2. Product Portfolio

                18.3.2.3. Financial Overview

                18.3.2.4. SWOT Analysis

                18.3.2.5. Strategic Overview

            18.3.3. Eli Lilly and Company

                18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.3.2. Product Portfolio

                18.3.3.3. Financial Overview

                18.3.3.4. SWOT Analysis

                18.3.3.5. Strategic Overview

            18.3.4. F. Hoffmann-La Roche Ltd.

                18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.4.2. Product Portfolio

                18.3.4.3. Financial Overview

                18.3.4.4. SWOT Analysis

                18.3.4.5. Strategic Overview

            18.3.5. GlaxoSmithKline plc

                18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.5.2. Product Portfolio

                18.3.5.3. Financial Overview

                18.3.5.4. SWOT Analysis

                18.3.5.5. Strategic Overview

            18.3.6. Novartis AG

                18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.6.2. Product Portfolio

                18.3.6.3. Financial Overview

                18.3.6.4. SWOT Analysis

                18.3.6.5. Strategic Overview

            18.3.7. Pfizer, Inc.

                18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.7.2. Product Portfolio

                18.3.7.3. Financial Overview

                18.3.7.4. SWOT Analysis

                18.3.7.5. Strategic Overview

            18.3.8. Sanofi

                18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.8.2. Product Portfolio

                18.3.8.3. Financial Overview

                18.3.8.4. SWOT Analysis

                18.3.8.5. Strategic Overview

            18.3.9. Takeda Pharmaceutical Company Limited

                18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.9.2. Product Portfolio

                18.3.9.3. Financial Overview

                18.3.9.4. SWOT Analysis

                18.3.9.5. Strategic Overview

            18.3.10. Teva Pharmaceutical Industries Ltd.

                18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.10.2. Product Portfolio

                18.3.10.3. Financial Overview

                18.3.10.4. SWOT Analysis

                18.3.10.5. Strategic Overview

    List of Tables

    Table 01: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031

    Table 02: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031

    Table 03: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031

    Table 04: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031

    Table 05: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031

    Table 06: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, Manufacturing Type, 2023-2031

    Table 07: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Region, 2023-2031

    Table 08: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031

    Table 09: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031

    Table 10: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031

    Table 11: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031

    Table 12: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031

    Table 13: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031

    Table 14: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031

    Table 15: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031

    Table 16: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031

    Table 17: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031

    Table 18: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031

    Table 19: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031

    Table 20: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031

    Table 21: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031

    Table 22: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031

    Table 23: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031

    Table 24: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031

    Table 25: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031

    Table 26: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031

    Table 27: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031

    Table 28: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031

    Table 29: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031

    Table 30: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031

    Table 31: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031

    Table 32: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031

    Table 33: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Type of Peptide, 2023-2031

    Table 34: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031

    Table 35: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031

    Table 36: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031

    Table 37: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031

    Table 38: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031

    Table 39: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031

    Table 40: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Type of Peptide, 2023-2031

    Table 41: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031

    Table 42: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031

    Table 43: Global Peptide Therapeutics Market: Company Share Analysis, 2022

    List of Figures

    Figure 01: Global Peptide Therapeutics Market Size, by Application, 2022

    Figure 02: Peptide Therapeutics Market share (%), by Application, 2022

    Figure 03: Peptide Therapeutics Market Size, by Route of Administration, 2022

    Figure 04: Peptide Therapeutics Market share (%), by Route of Administration, 2022

    Figure 05: Peptide Therapeutics Market Size, by Product Type, 2022

    Figure 06: Peptide Therapeutics Market share (%), by Product Type, 2022

    Figure 07: Peptide Therapeutics Market Size, by Types of Peptide, 2022

    Figure 08: Peptide Therapeutics Market share (%), by Types of Peptide, 2022

    Figure 09: Peptide Therapeutics Market Size, by Technology, 2022

    Figure 10: Peptide Therapeutics Market share (%), by Technology, 2022

    Figure 11: Peptide Therapeutics Market Size, by Manufacturing Type, 2022

    Figure 12: Peptide Therapeutics Market share (%), by Manufacturing Type, 2022

    Figure 13: Global Peptide Therapeutics Market, By Region (2022 and 2031)

    Figure 14: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, 2023-2031

    Figure 16: Global Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022

    Figure 15: Global Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 17: Global Peptide Therapeutics Market Value Share Analysis, by Product Type, 2031

    Figure 18: Global Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031

    Figure 19: Global Peptide Therapeutics Market Value (US$ Mn), by Innovative, 2023-2031

    Figure 20: Global Peptide Therapeutics Market Value Share Analysis, by Innovative, 2022 and 2031

    Figure 21: Global Peptide Therapeutics Market Value (US$ Mn), by Generic, 2023-2031

    Figure 22: Global Peptide Therapeutics Market Value Share Analysis, by Generic, 2022 and 2031

    Figure 23: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 24: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2022

    Figure 25: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2031

    Figure 26: Global Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031

    Figure 27: Global Peptide Therapeutics Market Value (US$ Mn), by Metabolic, 2023-2031

    Figure 28: Global Peptide Therapeutics Market Value Share Analysis, by Metabolic, 2022 and 2031

    Figure 29: Global Peptide Therapeutics Market Value (US$ Mn), by Oncology, 2023-2031

    Figure 30: Global Peptide Therapeutics Market Value Share Analysis, by Oncology, 2022 and 2031

    Figure 31: Global Peptide Therapeutics Market Value (US$ Mn), by Gastrointestinal, 2023-2031

    Figure 32: Global Peptide Therapeutics Market Value Share Analysis, by Gastrointestinal, 2022 and 2031

    Figure 33: Global Peptide Therapeutics Market Value (US$ Mn), by Cardiovascular, 2023-2031

    Figure 34: Global Peptide Therapeutics Market Value Share Analysis, by Cardiovascular, 2022 and 2031

    Figure 35: Global Peptide Therapeutics Market Value (US$ Mn), by Neurological, 2023-2031

    Figure 36: Global Peptide Therapeutics Market Value Share Analysis, by Neurological, 2022 and 2031

    Figure 37: Global Peptide Therapeutics Market Value (US$ Mn), by Others, 2023-2031

    Figure 38: Global Peptide Therapeutics Market Value Share Analysis, by Others, 2022 and 2031

    Figure 39: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration Type, 2022 and 2031

    Figure 40: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration Type, 2022

    Figure 41: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration Type, 2031

    Figure 42: Global Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration Type, 2023-2031

    Figure 43: Global Peptide Therapeutics Market Value (US$ Mn), by Parenteral, 2023-2031

    Figure 44: Global Peptide Therapeutics Market Value Share Analysis, by Parenteral, 2022 and 2031

    Figure 45: Global Peptide Therapeutics Market Value (US$ Mn), by Oral, 2023-2031

    Figure 46: Global Peptide Therapeutics Market Value Share Analysis, by Oral, 2022 and 2031

    Figure 47: Global Peptide Therapeutics Market Value (US$ Mn), by Others, 2023-2031

    Figure 48: Global Peptide Therapeutics Market Value Share Analysis, by Others, 2022 and 2031

    Figure 49: Global Peptide Therapeutics Market Value Share Analysis, by Types of Peptide Type, 2022 and 2031

    Figure 50: Global Peptide Therapeutics Market Value Share Analysis, by Types of Peptide Type, 2022

    Figure 51: Global Peptide Therapeutics Market Value Share Analysis, by Types of Peptide Type, 2031

    Figure 52: Global Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide Type, 2023-2031

    Figure 53: Global Peptide Therapeutics Market Value (US$ Mn), by Native Peptides, 2023-2031

    Figure 54: Global Peptide Therapeutics Market Value Share Analysis, by Native Peptides, 2022 and 2031

    Figure 55: Global Peptide Therapeutics Market Value (US$ Mn), by Analog Peptides, 2023-2031

    Figure 56: Global Peptide Therapeutics Market Value Share Analysis, by Analog Peptides, 2022 and 2031

    Figure 57: Global Peptide Therapeutics Market Value (US$ Mn), by Heterologous Peptides, 2023-2031

    Figure 58: Global Peptide Therapeutics Market Value Share Analysis, by Heterologous Peptides, 2022 and 2031

    Figure 59: Global Peptide Therapeutics Market Value Share Analysis, by Technology Type, 2022 and 2031

    Figure 60: Global Peptide Therapeutics Market Value Share Analysis, by Technology Type, 2022

    Figure 61: Global Peptide Therapeutics Market Value Share Analysis, by Technology Type, 2031

    Figure 62: Global Peptide Therapeutics Market Attractiveness Analysis, by Technology Type, 2023-2031

    Figure 63: Global Peptide Therapeutics Market Value (US$ Mn), by Liquid Phase, 2023-2031

    Figure 64: Global Peptide Therapeutics Market Value Share Analysis, by Liquid Phase, 2022 and 2031

    Figure 65: Global Peptide Therapeutics Market Value (US$ Mn), by Solid Phase, 2023-2031

    Figure 66: Global Peptide Therapeutics Market Value Share Analysis, by Solid Phase, 2022 and 2031

    Figure 67: Global Peptide Therapeutics Market Value (US$ Mn), by Hybrid, 2023-2031

    Figure 68: Global Peptide Therapeutics Market Value Share Analysis, by Hybrid, 2022 and 2031

    Figure 69: Global Peptide Therapeutics Market Value Share Analysis, Manufacturing Type, 2022 and 2031

    Figure 70: Global Peptide Therapeutics Market Value Share Analysis, Manufacturing Type, 2022

    Figure 71: Global Peptide Therapeutics Market Value Share Analysis, Manufacturing Type, 2031

    Figure 72: Global Peptide Therapeutics Market Attractiveness Analysis, Manufacturing Type, 2023-2031

    Figure 73: Global Peptide Therapeutics Market Value (US$ Mn), by In-house, 2023-2031

    Figure 74: Global Peptide Therapeutics Market Value Share Analysis, by In-house, 2022 and 2031

    Figure 75: Global Peptide Therapeutics Market Value (US$ Mn), by CMO, 2023-2031

    Figure 76: Global Peptide Therapeutics Market Value Share Analysis, by CMO, 2022 and 2031

    Figure 77: Global Peptide Therapeutics Market Value Share Analysis, by Region, 2022 and 2031

    Figure 78: Global Peptide Therapeutics Market Attractiveness Analysis, by Region, 2023-2031

    Figure 79: North America Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031

    Figure 80: North America Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031

    Figure 81: North America Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031

    Figure 82: North America Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 83: North America Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031

    Figure 84: North America Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 85: North America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 86: North America Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 87: North America Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031

    Figure 88: North America Peptide Therapeutics Market Value Share Analysis, by Types of Peptide, 2022 and 2031

    Figure 89: North America Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide, 2023-2031

    Figure 90: North America Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 91: North America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 92: North America Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031

    Figure 93: North America Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031

    Figure 94: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031

    Figure 95: Europe Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031

    Figure 96: Europe Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031

    Figure 97: Europe Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 98: Europe Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031

    Figure 99: Europe Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 100: Europe Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 101: Europe Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 102: Europe Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031

    Figure 103: Europe Peptide Therapeutics Market Value Share Analysis, by Types of Peptide, 2022 and 2031

    Figure 104: Europe Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide, 2023-2031

    Figure 105: Europe Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 106: Europe Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 107: Europe Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031

    Figure 108: Europe Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031

    Figure 109: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031

    Figure 110: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031

    Figure 111: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031

    Figure 112: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 113: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031

    Figure 114: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 115: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 116: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 117: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031

    Figure 118: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Types of Peptide, 2022 and 2031

    Figure 119: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide, 2023-2031

    Figure 120: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 121: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 122: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031

    Figure 123: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031

    Figure 124: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031

    Figure 125: Latin America Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031

    Figure 126: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031

    Figure 127: Latin America Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 128: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031

    Figure 129: Latin America Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 130: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 131: Latin America Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 132: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031

    Figure 133: Latin America Peptide Therapeutics Market Value Share Analysis, by Type of Peptide, 2022 and 2031

    Figure 134: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Type of Peptide, 2023-2031

    Figure 135: Latin America Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 136: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 137: Latin America Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031

    Figure 138: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031

    Figure 139: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031

    Figure 140: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031

    Figure 141: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031

    Figure 142: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 143: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031

    Figure 144: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 145: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 146: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031

    Figure 147: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031

    Figure 148: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Type of Peptide, 2022 and 2031

    Figure 149: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Type of Peptide, 2023-2031

    Figure 150: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 151: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 152: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031

    Figure 153: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031

    Figure 154: Global Peptide Therapeutics Market: Company Share Analysis, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved